The use of punctal plugs in the treatment of keratoconjunctivitis sicca (KCS) in inflammatory eye disease remains controversial because of the potentially increased retention time of tears enriched with inflammatory cytokines that may aggravate eye inflammation. We describe the safety and efficacy of punctal occlusion in a retrospective analysis of 19 patients (16 men) with KCS due to chronic GvHD (cGvHD). Efficacy and safety were assessed by subjective and objective criteria (symptoms, corneal fluorescein staining, tear film break-up time (BUT), Schirmer I test, Jones test and visual acuity). Follow-up was from plug insertion until maximum one year after punctal occlusion. After punctal occlusion, patients reported a significant increase in subjective comfort (1.10 vs 0.59 on a scale ranging from no symptoms (0) to severe impairment (2), Po0.001). Pathological corneal fluorescein staining decreased significantly (Po0.001) and tear film BUT remained unchanged (5.98 vs 4.0 s, P ¼ 0.79). Measurement of tear secretion or retention time showed a non-significant trend for improvement in the Schirmer I (3.0 vs 3.40 mm, P ¼ 0.08) and Jones (1.36 vs 2.8 mm, P ¼ 0.08) tests. The logMAR visual acuity remained unchanged. Punctal occlusion achieved a significant improvement in subjective symptoms and objective findings in ocular GvHD without increasing ocular inflammation.
INTRODUCTION
Allogeneic haematopoietic SCT is performed for the treatment of many diseases. One of the major success-limiting factors after transplantation is the development of GvHD, which may lead to severe functional impairment and a significant decrease in the quality of life.
Severe keratoconjunctivitis sicca (KCS) is frequently observed in chronic GvHD (cGvHD) and was proposed as a distinctive sign of cGvHD in the NIH Consensus Development Project. 1 Dry eyes due to lacrimal and conjunctival dysfunction are the most frequent complication in ocular GvHD. 2 Balanced tear film quality and quantity are important to maintain adequate moisturisation, lubrication and nutrition of the cornea, and hence are prerequisites for normal vision. Severe KCS may even lead to corneal ulceration and perforation with loss of vision. Hypotheses for the aetiology of dry eyes in cGvHD are lacrimal gland inflammation and destruction, as well as ocular surface inflammation, leading to decreased tear volume (quantity) and altered tear composition (quality). The efficacy of systemic and topical immunomodulation and corticosteroids is often limited and may be associated with secondary complications, such as infections, cataract formation and glaucoma. Current topical treatment options for dry eyes include various topical lubricants that help to relieve symptoms in many patients. Application of autologous serum eye drops, therapeutic contact lenses or topical cyclosporine may also reduce symptoms in some patients. However, none of these interventions restores the physiological tear film. Hence for patients insufficiently responding to such treatments, punctal occlusion with punctal plugs may be additionally indicated. These plugs are placed in the inferior and/or superior punctum to occlude the opening, thereby reducing the outlet of the few tears produced, which increases the retention time, and hence the moistness of the outer eye. Although punctal occlusion is often used in patients with classic dry eye, an isolated study on the short-and long-term feasibility and efficacy has not been performed in patients with inflammatory dry eyes after allogeneic haematopoietic SCT for fear of the possible increase of pro-inflammatory cytokines in their tears. 3 
PATIENTS AND METHODS
Between 2005 and 2011, 19 patients (16 men) with mild-to-severe KCS due to ocular cGvHD from a single centre were treated with punctal plugs and analysed retrospectively. Punctal occlusion was performed in patients with severe KCS at the onset of ocular cGvHD or in patients under topical treatment with unsatisfactory response. The punctal plugs and sizes used varied according to the preferences of the ophthalmologist and the punctal conditions, and included preloaded silicone punctal plugs designed by JA Bernard (FCI Ophthalmics, Pembroke, MA, USA), Smart plugs (AIVIMED, Wiesbaden, Germany) and Herrick lacrimal plugs (Lacrimedics, Eastsound, WA, USA). In some patients, a short-term resorbable collagen plug was initially implanted (Gellansert, EagleVision, Memphis, TN, USA) to test the efficacy of intervention before implanting a definitive plug.
Efficacy was assessed during repeated consultations based on symptoms and objective criteria. Signs and symptoms were sequentially assessed from the onset of ocular GvHD. Data reviewed during follow-up included actual local and systemic therapy for GvHD, severity of complaints, corneal fluorescein staining, tear film break-up time (BUT), Schirmer I and Jones tests, logMAR visual acuity, type and localisation of punctal plugs, and their complications and frequency of spontaneous extrusion. Here we report the results until maximum 1-year follow-up after punctal plug implantation. Additional patient data were retrospectively recorded by chart review and included sex, age, type of transplantation, underlying diseases, and other manifestations of cGvHD and immunosuppressive treatment.
The severity of the subjective complaints was rated as 0 (no dry eye symptoms), 1 (complaints of dry eye symptoms not or partially affecting the daily activities without visual impairment) or 2 (dry eye symptoms significantly affecting daily activities or inability to work because of ocular complaints or reported loss of vision due to KCS).
Fluorescein staining was performed using fluorescein strips to evaluate ocular surface damage. Fluorescein dye was instilled on the inferior palpebral conjunctiva and the patient was instructed to blink. Corneal staining was recorded using slit-lamp cobalt blue for assessment. Fluorescein staining of the cornea was rated as 0 (no staining), 1 (staining covering an area of o30%) or 2 (coalescent staining over a wide area of 430%).
In a similar manner of preparation as for fluorescein staining, tear film BUT was measured by the latency to the first appearance of a black spot in the fluorescein-coloured surface of the cornea after complete closure of the eyelid.
To evaluate stimulated tear production, the Schirmer I test was performed without anaesthetic by placing a standardised strip (Schirmer-Plus, Gecis, Neung sur Beuvron, France) in the lateral third of the eye over the inferior lid margin. The patient was instructed to keep the eyes open and the length of the tear track was measured in mm after 5 min. Using a similar procedure, basal tear production was determined by Jones test after the application of one drop of local anaesthetic (Alcaine, Alcon, Basel, Switzerland).
Best spectacle-corrected distance visual acuity was measured in all patients. Changes in subjective complaints, corneal fluorescein staining, tear film BUT, Schirmer I and Jones tests, and logMAR visual acuity before and after punctal plug implantation were compared by the Wilcoxon signed-rank test. A P value of o0.05 was considered statistically significant. SPSS 14.0 (IBM, NY, USA) was used for statistical analysis.
The study was approved by the local ethical board and conducted in accordance with the tenets of the Declaration of Helsinki.
RESULTS
Between 2005 and 2011, 37 eyes in 19 patients (1 monoculus) were treated with punctal plugs for KCS from ocular cGvHD. The patient characteristics are summarised in Table 1 .
The median time interval between transplantation and diagnosis of ocular cGvHD was 711 days (range 189 --4666 days). At this time, 18 patients had active cGvHD manifestations in other organs. Diagnosis of cGvHD was therefore made by diagnostic signs in other organs. At the time of diagnosis of ocular GvHD, 18 patients were already under systemic immunosuppressive therapy with a calcineurin inhibitor (n ¼ 13) or calcineurin inhibitor and prednisone (n ¼ 5). In two patients, steroid treatment was started at the time of diagnosis of ocular cGvHD. Plug insertion was performed in a majority of patients at the time of formal diagnosis of ocular GvHD (range 0 --1006 days after diagnosis of ocular cGvHD).
After punctal occlusion, a significant subjective improvement was quickly observed, with an average decrease of subjective complaints from 1.10 (±0.36) to 0.59 (±0.46) during the followup period of 12 months (Po0.001, Figure 1 ). There was also a significant decrease of corneal staining from 1.07 ( ± 0.42) to 0.75 (±0.43) (Po0.001, Figure 1 ).
There was no significant change in BUT (5.98 ± 2.38 vs 4.0 ± 3.46 s; P ¼ 0.79). Stimulated and basal tear production did not change significantly as measured by Schirmer I (3.0±4.93 vs 3.40±2.58 mm; P ¼ 0.08) and Jones (1.36±1.85 vs 2.8±2.12 mm, P ¼ 0.08) tests ( Figure 2) ; logMAR visual acuity remained constant at 0.11 (P ¼ 0.73, Figure 3) .
Documented plug reinsertion because of spontaneous loss was performed in 22 of 37 eyes (59%), sometimes recurrently. When considering both lacrimal puncta in each eye, the first documented punctal plug loss occurred in average after 147 days (±141 days). Punctal plug implantation did not lead to direct discomfort, increased ocular inflammation, ocular infections or other adverse events in any patients.
Median follow-up after plug insertion was 327 days (range 34 --925 days). During the last follow-up, plugs were intact in 18 patients. In one patient, permanent punctal occlusion was surgically induced because of repeated spontaneous plug loss. In all other patients, no surgical interventions were necessary or planned. Fifteen patients were under immunosuppressive treat- ment with calcineurin inhibitors (14) or sirolimus; 1 six were under a combination treatment with prednisone and one with imatinib.
DISCUSSION
Ocular GvHD is observed in more than 50% of patients with cGvHD after allogeneic haematopoietic SCT. It may affect all parts of the eye, but KCS is its most common ocular manifestation. KCS usually develops together with inflammatory signs of conjunctivitis, such as conjunctival oedema, chemosis and pseudomembrane formation, and chronic blepharitis. This process may lead to secondary epithelial changes such as punctate keratopathy, the formation of filaments, painful erosions and secondary corneal infections, and is even associated with ulceration and perforation of the cornea. Patients with ocular GvHD, particularly when on immunosuppressive treatment, may develop infectious conjunctivitis, blepharitis, keratitis and even endophthalmitis, which can all lead to permanent visual loss. 2,4 --6 Controversial recommendations are given regarding punctal occlusion for patients suffering from ocular GvHD. Behrens et al. 3 fear that because of 'the possible presence of non-clinically apparent inflammation, punctal plugs could result in retention of proinflammatory tear components on the ocular surface and may enhance damage to the ocular surface, accelerate the disease process and produce greater patient discomfort', and advise against punctal occlusion. On the other hand Couriel et al. and Riemens et al. 7, 8 leave the option of using punctal occlusion as an ancillary therapy in GvHD patients.
Punctal plug treatment led to a significant subjective and objective improvement in KCS due to chronic ocular GvHD. After punctal occlusion, our patients had significantly less dry eye discomfort and lower corneal staining scores. Except for spontaneous plug loss, which happened in 59% of the plugged eyes, there were no adverse events indicated by the patients or diagnosed by the ophthalmologist. Consistent with our results, previous studies have shown that spontaneous plug loss is the most common problem with punctal plugs, occurring in 30 --50%. 9, 10 Other known possible complications of punctal occlusion include pruritus, discomfort, lesions of the conjunctiva and cornea, epiphora, canaliculitis and pyogenic granuloma. 11 None of the aforementioned was observed in our study. Contraindications of punctal plug implantation are observed in patients with known sensitivity to the particular material, dacryocystitis and infectious conjunctivitis. 12 Despite the often-discussed and assumed higher concentration of proinflammatory factors in the tear film after punctal plug insertion because of increased retention time, 3, 13 we could not find any signs of increased ocular inflammation after the insertions. Ogawa et al.
14 reported on 14 ocular GvHD patients with autologous serum eye drops 10 times/day (2 --3 drops each time). In six patients who worsened or did not improve after at least 1 month after starting the treatment, punctal occlusion was added using silicone plugs. In all of these patients complete or nearly complete resolution of all symptoms and objective findings was achieved. Mansour et al. 15 examined lacrimal punctal occlusion in patients suffering from KCS due to Sjö gren's syndrome, which has similar pathophysiological mechanisms to ocular GvHD, and consistent with our findings showed a significant subjective and objective improvement of dry eye manifestation in these patients. One may hypothesise that the larger the amount of tears present, the proinflammatory cytokines may become more diluted. Another possible explanation is the already-delayed tear turnover present in the dry eye state. 16 With a delayed turnover, local anti-inflammatory treatment could be more effective.
Besides the systemic medication for cGvHD of the eyes, local treatment aims to decrease ocular surface inflammation and increase ocular surface moisture. 7 The beneficial effect of steroids and other immunomodulatory drugs in chronic inflammatory eye conditions has been documented. Robinson et al. 17 demonstrated the effectiveness of therapy with a topical corticosteroid for cicatricial conjunctivitis associated with cGvHD. Marsh et al. significant improvement in symptom scores, corneal sensitivity, tear evaporation rate, BUT, staining scores, goblet cell density, conjunctival squamous metaplasia grade and inflammatory cell numbers. Cyclosporine exerts its immunosuppressive effects through suppression of calcineurin-mediated T lymphocyte activation and downregulation of inflammatory cytokines. 20 Even if the exact pathogenesis of ocular cGvHD is unknown, it seems relevant that the above-described processes make an important contribution to ocular GvHD.
There are many possibilities to improve ocular surface moisture, including lubrification using artificial tears and serum drops, control of evaporation by regular lid care techniques, moisture chamber goggles, tarsorrhaphy and punctal occlusion. 14, 17 Particularly, in the case of ocular GvHD treatment, the use of punctal plugs has been controversial because of lack of data. Under conditions of punctal occlusion, corneal sensation and tear turnover are altered, thus allowing an increased contribution of local inflammatory cytokines in the pathophysiology of dry eye. 21 Our study has a few limitations. Because of the retrospective design, some data during the follow-up visits are missing. As these tests are performed more often when an increase of signs or symptoms occur, we may underestimate the effect of plug insertion. In addition, patient's subjective complaints and objective corneal staining, as recorded in the medical history in an unblinded score, may be sources of imprecise data. Because of this, additional investigations for the effects of punctal occlusion in patients with ocular GvHD are required. However, we were able to prove that no disadvantage is induced by punctal occlusion in patients with ocular GvHD and no severe side effect was observed.
In conclusion, in contrast to current concerns, ocular GvHD is not a contraindication for punctal occlusion with punctal plugs. Plug implantation is safe and effective, which results in significant improvement in subjective symptoms and objective findings in ocular GvHD. The optimal time for plug implantation and its combination with other topical and systemic treatment still needs to be determined.
